Patents by Inventor Emmanuel Bey

Emmanuel Bey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2
    Patent number: 9884839
    Abstract: Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17?-HSD1 and 17?-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: February 6, 2018
    Assignee: ElexoPharm GmbH
    Inventors: Rolf Hartmann, Martin Frotscher, Ahmed Saad Abdelsamie Ahmed, Emmanuel Bey, Chris J. van Koppen, Sandrine Oberwinkler-Marchais, Carsten Börger, Lorenz Siebenbürger, Victor Hernández Olmos
  • Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2
    Publication number: 20160318895
    Abstract: Provided herein are non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 and type 2 (17?-HSD1 and 17?-HSD2) inhibitors, their production and use, especially for the treatment and for prophylaxis of hormone-related diseases.
    Type: Application
    Filed: January 5, 2015
    Publication date: November 3, 2016
    Inventors: Rolf Hartmann, Martin Frotscher, Ahmed Saad Abdelsamie Ahmed, Emmanuel Bey, Chris J. van Koppen, Sandrine Oberwinkler-Marchais, Carsten Börger, Lorenz Siebenbürger, Victor Hernández Olmos
  • Aldosterone synthase inhibitors
    Patent number: 9278093
    Abstract: This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: March 8, 2016
    Assignees: Merck Sharp & Dohme Corp., ElexoPharm GmbH
    Inventors: Amjad Ali, Emmanuel Bey, Rolf Hartmann, Quingzhong Hu, Lina Yin
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20150306091
    Abstract: This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Application
    Filed: March 29, 2013
    Publication date: October 29, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Emmanuel Bey, Rolf Hartmann, Quingzhong Hu, Lina Yin
  • Aldosterone synthase inhibitors
    Patent number: 9073929
    Abstract: This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: July 7, 2015
    Assignees: ElexoPharm GmbH, Merck Sharp & Dohme Corp.
    Inventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
  • ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20140045819
    Abstract: This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Application
    Filed: April 20, 2012
    Publication date: February 13, 2014
    Applicants: ElexoPharm GmbH, SCHERING CORPORATION
    Inventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
  • 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS FOR THE TREATMENT OF HORMONE-RELATED DISEASES
    Publication number: 20110046147
    Abstract: The invention relates to 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) inhibitors, the preparation thereof and the use thereof for the treatment and prophylaxis of hormone-related, especially estrogen-related or androgen-related, diseases.
    Type: Application
    Filed: August 22, 2008
    Publication date: February 24, 2011
    Applicant: UNIVERSITAT DES SAARLANDES
    Inventors: Rolf Hartmann, Martin Frotscher, Sandrine Oberwinkler, Emmanuel Bey